Five Prime Therapeutics (FRPX) PT Raised to $60 at Jefferies

August 5, 2016 9:51 AM EDT
Get Alerts FPRX Hot Sheet
Price: $57.46 +1.00%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade FPRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $60.00 (from $41.00) following Q2 results.

Yang commented, "Narrower 2Q net loss on higher revenue; estimated YE16 cash of ~$400M should fund operations into ~2019 by our est's. With ample cash, a sustainable, growing pipeline fueled by its drug discovery engine & potential from ongoing I/O partnership with BMY, we're upping PT to $60 on what we view as favorable risk/reward at current EV of ~$900M."

For an analyst ratings summary and ratings history on Five Prime Therapeutics click here. For more ratings news on Five Prime Therapeutics click here.

Shares of Five Prime Therapeutics closed at $51.59 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment